Data from an open-label, multicenter Phase 1 study of an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS, formerly TAR-210) in FGFR-altered non-muscle-invasive bladder cancer were presented at the European Association of Urology 2026 Annual Meeting. As of Nov. 3, 2025, 62 patients with recurrent intermediate-risk disease and 26 patients with recurrent BCG-experienced high-risk disease had received treatment. In the intermediate-risk cohort, the complete response rate was 89% and the median duration of complete response was 18 months. In the high-risk cohort, median recurrence-free survival was 20 months and 12-month recurrence-free survival was 83%. Across both cohorts, the most frequent treatment-related adverse events were hematuria (32%) and dysuria (22%).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603131235PR_NEWS_USPR_____NY02613) on March 13, 2026, and is solely responsible for the information contained therein.